Last reviewed · How we verify
TAK-672
At a glance
| Generic name | TAK-672 |
|---|---|
| Also known as | rpFVIII, TAK-672, Obizur |
| Sponsor | Takeda |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
- A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
- Study of TAK-672 in Participants With Acquired Hemophilia A (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-672 CI brief — competitive landscape report
- TAK-672 updates RSS · CI watch RSS
- Takeda portfolio CI